课题基金 / 基金详情

Improving Medication Adherence in adolescents who had a Liver Transplant: iMALT

Improving Medication Adherence in adolescents who had a Liver Transplant: iMALT
改善接受肝移植的青少年的药物依从性:iMALT
批准号:
10021643
负责人:
EYAL SHEMESH
金额:
$99.7万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-20 至 2023-08-31

项目摘要

项目成果

EYAL SHEMESH的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This submission brings together leading pediatric transplant centers, using the NIDDK's collaborative multisite trial (U01) grant mechanism, to investigate an innovative strategy to improve transplant outcomes by improving adherence to medication regimens. Nonadherence to immunosuppressant medications is the leading cause of organ rejection in adolescent transplant recipients. We will investigate a tailored telemetric intervention reduce the number of patients who have a rejection by improving adherence to medications in adolescents who had a liver transplant. This study will use the Medication Level Variability Index (MLVI) to inform the intervention. The MLVI is an innovative biomarker of adherence which calculates the degree of variability between immunosuppressant medication blood levels over time (higher variability = worse adherence). It is a robust predictor of organ rejection (MLVI>2 denotes clinically significant nonadherence, leading to higher rejection risk). At-risk adolescent liver transplant recipients (MLVI>2) will be enrolled in a randomized controlled trial across several transplant centers. In the active telemetric intervention arm (administered via telephone, FaceTime ® or Skype ® interfaces), experienced interventionists will remotely communicate with patients using a standardized but flexible intervention strategy. The intervention includes addressing psychological avoidance associated with self-care, and further includes reminders and problem- solving of identified barriers to adherence. Control arm participants will continue to receive standard-of-care at the site. The study will exclusively enroll at-risk patients, will continually monitor their progress through the MLVI marker, and will tailor the intervention to the adherence monitoring findings throughout the 2 year trial period. This study will thus investigate an innovative “personalized medicine” approach to target a remote intervention effort.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Improving Medication Adherence in adolescents who had a Liver Transplant: iMALT
Improving Medication Adherence in adolescents who had a Liver Transplant: iMALT
Improving Medication Adherence in adolescents who had a Liver Transplant: iMALT
Improving Medication Adherence in adolescents who had a Liver Transplant: iMALT
海外基金